Diabetes due to a progressive defect in β-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): A new model for type 2 diabetes

Diabetes

Volumn 53, Issue 6, 2004, Pages 1509-1516

  Butler, Alexandra E ^a   Jang, Jennifer ^a   Gurlo, Tatyana ^a   Carty, Maynard D ^b   Soeller, Walter C ^b   Butler, Peter C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; GLUCOSE; INSULIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; HYPERGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; SOUTHERN BLOTTING; TRANSGENIC ANIMAL; TRANSGENIC MOUSE;

AGING; AMYLOID; ANIMALS; ANIMALS, GENETICALLY MODIFIED; APOPTOSIS; BLOOD GLUCOSE; BODY WEIGHT; CELL DIVISION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; INSULIN; ISLETS OF LANGERHANS; OSMOLAR CONCENTRATION; RATS;

EID: 2542581025     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.6.1509     Document Type: Article

References (43)

1. Cavaghan MK, Ehrmann DA, Polonsky KS: Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 106:329-333, 2000
2. LeRoith D: Beta-cell dysfunction and insulin resistance in type-2 diabetes: role of metabolic and genetic abnormalities. Am J Med 113 S6A:3S-11S, 2002
3. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU: Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4:110-125, 1985
4. Butler AE, Juliette J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110, 2003
5. Lorenzo A, Razzaboni B, Weir GC, Yankner BA: Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368: 756-760, 1994
6. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediatesized toxic amyloid particles. Diabetes 48:491-498, 1999
7. Ritzel RA, Butler PC: Replication increases β-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 52:1701-1708, 2003
8. Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang D, Chang JK, Rizza RA: Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 39:752-756, 1990
9. Butler PC: Islet amyloid and its potential role in the pathogenesis of type II diabetes mellitus. In Diabetes Mellitus: A Fundamental and Clinical Text. LeRoith D, Taylor SI, Olefsky JM, Eds. Philadelphia, Lippincott, William, and Wilkins, 1996, p. 113-117
10. Ohsawa H, Kanatsuka A, Yamaguchi T: Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun 160:961-967, 1989
11. Maloy AL, Longnecker DS, Greenberg ER: The relation of islet amyloid to the clinical type of diabetes. Hum Pathol 12:917-922, 1981
12. Narita R, Toshimori H, Nakazato M, Kuribayashi T, Toshimori T, Kawabata K, Takahashi K, Masukura S: Islet amyloid polypeptide (IAPP) and pancreatic islet amyloid deposition in diabetic and non-diabetic patients. Diabetes Res Clin Pract 15:3-14, 1992
13. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Glabe CG: Common structure of soluble amyloid oligomers implies common mechanism of athogenesis. Science 300:486-489, 2003
14. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr: Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418:291, 2002
15. Betsholtz C, Christmanson L, Engstrom U, Rorsman F, Jordan K, O'Brien TD, Murtaugh M, Johnson KH, Westermark P: Structure of cat islet amyloid polypeptide and identification of amino acid residues of potential significance for islet amyloid formation. Diabetes 39:118-122, 1990
16. Jordan K, Murtaugh MP, O'Brien TD, Westermark P, Betsholtz C, Johnson KH: Canine IAPP cDNA sequence provides important clues regarding diabetogenesis and amyloidogenesis in type 2 diabetes. Biochem Biophys Res Commun 169:502-507, 1990
17. Ohagi S, Nishi M, Bell GI, Ensinck JW, Steiner DF: Sequences of islet amyloid polypeptide precursors of an old world monkey, the pig-tailed macaque (Macaca nemestrini), and the dog (Canis familiaris). Diabetelogia 34:555-558, 1991
18. Westermark P, Engstrom U, Johnson KH, Westermark GT: Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87:5036-5040, 1990
19. O'Brien TD, Butler PC, Westermark P, Johnson KH: Islet amyloid polypeptide: a review of its biology and potential roles in the pathogenesis of NIDDM. Vet Pathol 30:317-332, 1993
20. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, Butler PC: Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Ntnl Acad Sci U S A 93:7283-7288, 1996
21. Couce M, Kane LA, O'Brien TD, Charlesworth J, Soeller W, McNeish J, Kreutter D, Roche P, Butler PC: Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction. Diabetes 45:1094-1101, 1996
22. Hoppener JW, Oosterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JH, Vroom TM, Ahren B, Lips CJ: Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42:427-434, 1999
23. Butler AE, Janson J, Soeller WC, Butler PC: Increased β-cell apoptosis prevents adaptive increase in β-cell mass in mouse model of type-2 diabetes. Diabetes 52:2304-2314, 2003
24. vy/a mice expressing human islet amyloid polypeptide. Diabetes 47:743-750, 1998
25. Bonner-Weir S: Islet growth and development in the adult. J Mol Endocrinol 24:297-302, 2000
26. Finegood DT, Scaglia L, Bonner-Weir S: Dynamics of β-cell mass in the growing rat pancreas: estimation with a simple mathematical model. Diabetes 44:249-256, 1995
27. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY: Glucose induced beta cell production of IL-1 beta contributes to glucose toxicity in human pancreatic islets. J Clin Invest 110:851-860, 2002
28. Efanova BE, Zaitsev SV, Zhivotovsky B, Kohler M, Efendic S, Orrenius S, Berggren P-O: Glucose and tolbutamide induce apoptosis in pancreatic beta cells. J Biol Chem 273:33501-33507, 1998
29. Tokuyama Y, Sturis J, DePaoli AM, Takeda J, Stoffel M, Tang J, Sun X, Polonsky KS, Bell GI: Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 44:1447-1457, 1995
30. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, Polonsky KS: Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes 47:358-364, 1998
31. Finegood DT, McArthur MD, Kojwangt D, Thomas MJ, Topp BG, Leonard T, Buckingham RE: β-Cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes 50:1021-1029, 2001
32. Takaya K, Ogawa Y, Isse N, Okazaki T, Satoh N, Masuzaki H, Tamura N, Hosada K, Nakao K: Molecular cloning of rat leptin receptor isoform complementary DNAs: identification of missense mutation in Zucker fatty (fa/fa) rats. Biochem Biophys Res Commun 225:75-83, 1996
33. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CT, Hess JF: Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 13:18-19, 1996
34. Shimabukuro M, Zhou Y-T, Levi M, Unger RH: Fatty acid-induced β-cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 95:2498-2502, 1998
35. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH: Beta-cell lipotoxicity in the pathogenesis of non-insulin dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A 91:10878-10882, 1994
36. Lee Y, Hirose H, Zhou Y-T, Esser V, McGarry JD, Unger RH: Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes 46:408-413, 1997
37. Adler JH, Kalman R, Lazarovici G, Bar-On H, Ziv E: Achieving predictable model of type 2 diabetes in the sand rat. In Frontiers in Diabetic Research: Lessons from Animal Diabetes III. Shafrir E, Ed. London, Smith-Gordon, 1991, p. 212-214
38. Donath MY, Gross DJ, Cerasi E, Kaiser N: Hyperglycemia-induced β-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 48:738-744, 1999
39. Goto Y, Suzuki KI, Sasaki M, Ono T, Abe S: GK rat as a model of non-obese, non-insulin dependent diabetes: selective breeding over 35 generations. In Lessons from Animal Studies II. Shafrir E, Reynold AE, Eds. London, Libbey, 1998, p. 301-303
40. Movassat J, Saulnier C, Serradas P, Portha B: Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia 40:916-925, 1997
41. Serradas P, Gangnerau MN, Giroix MH, Saulnier C, Potha B: Impaired pancreatic beta cell function in the fetal GK rat: impact of diabetic inheritance. J Clin Invest 101:899-904, 1998
42. Plachot C, Movassat J, Portha B: Impaired beta cell regeneration after partial pancreatectomy in the adult Goto-Kakizaki rat, a spontaneous model of type II diabetes. Histochem Cell Biol 116:131-139, 2001
43. Serradas P, Goya L, Lacorne M, Gangnerua M-N, Ramos S, Alvarez C, Pascual-Leone A-M, Portha B: Fetal insulin-like growth factor-2 production is impaired in the GK rat model of type 2 diabetes. Diabetes 51:392-397, 2002